Beam Therapeutics

Short description: American healthcare company

Beam Therapeutics Inc.Type| Public company

|

Traded as

* NASDAQ: BEAM
* Russell 2000 component

ISIN| US07373V1052
Industry| Biotechnology
Founded| 2017; 9 years ago (2017)
Founders|

* David R. Liu
* J. Keith Joung
* Feng Zhang
* Nicole Gaudelli
* Alexis Komor

Headquarters| Cambridge, Massachusetts, U.S.

Key people

* John Evans, CEO
* Giuseppe Ciaramella, CSO

Number of employees

| 341 (December 31, 2021)[1]
Website| beamtx.com

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods[vague].[2][3]

## Contents

* 1 History
* 2 See also
* 3 References
* 4 External links

## History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.[5]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[6][7]

## See also

* CRISPR Therapeutics
* Intellia Therapeutics
* Editas Medicine

## References

1. ↑ "Beam Therapeutics Inc. FORM 10-K". https://www.sec.gov/ix?doc=/Archives/edgar/data/1745999/000095017022002166/beam-20211231.htm.
2. ↑ "Why Beam Therapeutics Climbed 64.5% in June". https://www.nasdaq.com/articles/why-beam-therapeutics-climbed-64.5-in-june-2021-07-08.
3. ↑ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy" (in en-US). https://www.genengnews.com/news/base-editing-shows-promise-as-common-lung-and-liver-disease-therapy/.
4. ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.
5. ↑ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma" (in en-US). https://www.businessinsider.com/biotech-gene-editing-crispr-intellia-beam-verve-inside-lab-2021-7.
6. ↑ "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research.
7. ↑ Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases" (in en-US). https://www.barrons.com/articles/pfizer-beam-therapeutics-gene-editing-diseases-partnership-51641678989.

## External links

* Official website
* Business data for Beam Therapeutics Inc.:

* Google Finance
* Yahoo! Finance
* Bloomberg
* Reuters
* SEC filings

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Beam Therapeutics. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Beam_Therapeutics&oldid=831558"